NL-OMON54425
Recruiting
Phase 4
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis. - Connect&Go
ConditionsNSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- NSCLC and head and neck cancer
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 390
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age \>\=18 years;
- •\- Able and willing to give written informed consent;
- •\- Planned treatment with nivolumab or pembrolizumab monotherapy (subjects
- •treated with nivolumab/ipilimumab combination treatment can participate in the
- •trial on days during which they receive nivolumab monotherapy) or any other EMA
- •approved ICI as monotherapy for any EMA approved indication and with any dose;
- •\- Adequate Dutch language proficiency (at least proficiency level C1\)
- •\- At least 2 prior cycles of Nivolumab or Pembrolizumab therapy
- •\- At least 4 remaining cycles of Nivolumab or Pembrolizumab monotherapy after
- •inclusion in the study.
Exclusion Criteria
- •Prior infusion related reactions to Nivolumab or Pembrolizumab (any grade).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
Not yet recruiting
Not Applicable
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.JPRN-UMIN000050723Kobe University200
Completed
Not Applicable
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanomaJPRN-UMIN000026925Kochi University, Kochi Medical School5
Active, not recruiting
Phase 1
Pre-operative immunotherapy in early-stage colon cancersEUCTR2016-002940-17-NLAntoni van Leeuwenhoek155